Literature DB >> 12936704

Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes.

D Projean1, P-E Morin, T M Tu, J Ducharme.   

Abstract

1. The aim was to identify the cytochrome P450 (CYP) enzymes responsible for the N-demethylation of morphine in vitro. 2. In human liver microsomes, normorphine formation followed Michaelis-Menten kinetics with mean Km and Vmax of 12.4 +/- 2.2 mM and 1546 +/- 121 pmol min(-1) mg(-1), respectively. In microsomes from a panel of 14 human livers phenotyped for 10 CYP enzymes, morphine N-demethylation correlated with testosterone 6beta-hydroxylation (r=0.91, p<0.001) and paclitaxel 6-alpha hydroxylation (r=0.72, p<0.001), two specific markers of CYP3A4 and CYP2C8, respectively. Normorphine formation decreased when incubated in the presence of troleandomycin or quercetin (by 46 and 33-36%, respectively), which further corroborates the contribution of CYP3A4 and CYP2C8. 3. Among eight recombinant human CYP enzymes tested, CYP3A4 and CYP2C8 exhibited the highest intrinsic clearance. More than 90% of morphine N-demethylation could be accounted for via the action of both CYP3A4 and CYP2C8. 4. The in vitro findings suggest that hepatic CYP3A4, and to a lesser extent CYP2C8, play an important role in the metabolism of morphine into normorphine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12936704     DOI: 10.1080/0049825031000121608

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  18 in total

Review 1.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

2.  Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Authors:  Akash Khandelwal; Praveen M Bahadduri; Cheng Chang; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

Review 3.  Opioid metabolism.

Authors:  Howard S Smith
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

4.  Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.

Authors:  Pallabi Mitra; Jürgen Venitz; Yunyun Yuan; Yan Zhang; Phillip M Gerk
Journal:  Drug Metab Dispos       Date:  2011-06-17       Impact factor: 3.922

5.  Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics.

Authors:  Konrad Meissner; Michael J Avram; Viktar Yermolenka; Amber M Francis; Jane Blood; Evan D Kharasch
Journal:  Anesthesiology       Date:  2013-10       Impact factor: 7.892

6.  The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects.

Authors:  M W Hruska; J A Amico; T Y Langaee; R E Ferrell; S M Fitzgerald; R F Frye
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

7.  Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.

Authors:  Elizabeth B Daily; Christina L Aquilante
Journal:  Pharmacogenomics       Date:  2009-09       Impact factor: 2.533

Review 8.  PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.

Authors:  Christina L Aquilante; Mikko Niemi; Li Gong; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2013-12       Impact factor: 2.089

9.  Effective virtual screening protocol for CYP2C9 ligands using a screening site constructed from flurbiprofen and S-warfarin pockets.

Authors:  Tímea Polgár; Dóra K Menyhárd; György M Keseru
Journal:  J Comput Aided Mol Des       Date:  2007-10-25       Impact factor: 3.686

10.  The feasibility of physiologically based pharmacokinetic modeling in forensic medicine illustrated by the example of morphine.

Authors:  Nadine Schaefer; Daniel Moj; Thorsten Lehr; Peter H Schmidt; Frank Ramsthaler
Journal:  Int J Legal Med       Date:  2017-12-01       Impact factor: 2.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.